Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma Clinical Trial

Official title:
A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Status Completed

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Multiple Myeloma
Neoplasms, Plasma Cell
Relapse/Refractory Multiple Myeloma

Clinical Trial Details

NCT number	NCT02290431
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	December 16, 2014
Completion date	December 25, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03944057` - A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT06084962` - A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma	Phase 1
Active, not recruiting	`NCT04613557` - Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma	Phase 1
Completed	`NCT03353545` - Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions
Withdrawn	`NCT02985333` - Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	Phase 2
Withdrawn	`NCT02986451` - Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma	Phase 2